← Human Trials & Peer-Reviewed Studies
Dose-response effects on HbA(1c) and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial
Plain-language guide to PMID 38095657 (2024): double-blind randomized controlled trial study of Semaglutide and Survodutide.
Key Facts
- PMID
- 38095657
- Journal
- Diabetologia
- Year
- 2024
- Study type
- Randomized Controlled Trial
- Authors
- Blüher M et al. (5 authors)
- DOI
- 10.1007/s00125-023-06053-9
What This Study Did, in Plain Language
What Was Tested
Researchers studied Semaglutide and Survodutide in this randomized controlled trial publication.
ClinicalTrials.gov NCT04153929 and EudraCT 2019-002390-60.
Who Took Part
Participants and all those involved in the trial conduct/analysis were blinded; the semaglutide arm was open-label.
The primary endpoint was absolute change from baseline in HbA1c after 16 weeks' treatment.
How the Study Was Run
The design is described as randomized, double-blind, open-label, placebo-controlled, multicenter and parallel-group.
Because people in this Semaglutide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Blinding on both sides kept the participants and researchers unaware of who received Semaglutide.
Nothing was hidden in this open-label Semaglutide study: the participants and staff both knew the treatment.
The comparison arm used a placebo, so changes seen with Semaglutide could be set against what happens without it.
A time span of 16 weeks appears in the methods.
The key secondary endpoint was relative change from baseline in bodyweight after 16 weeks' treatment.
What Was Measured
Topics PubMed links to this paper include Diabetes Mellitus, Type 2, Hypoglycemic Agents, Glucagon, Glucagon-Like Peptide-1 Receptor Agonists, Glucagon-Like Peptide 1, Glucagon-Like Peptides and Peptides.
Author keywords: Bodyweight loss, Dual incretin agonist, Obesity, Semaglutide, Survodutide and Type 2 diabetes.
What This Means in Plain Language
The paper is a randomized, double-blind and open-label study of Semaglutide and Survodutide over 16 weeks.
Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2024 (Diabetologia), a journal based in Germany.
More context: the Semaglutide compound page and the Survodutide compound page, all human trials.
Our Notes on the Compounds
Semaglutide: The active ingredient in several prescription GLP-1 receptor agonist medicines (Ozempic, Wegovy, oral tablets).
Survodutide: An investigational long-acting GLP-1 and glucagon receptor dual agonist studied for obesity and metabolic liver disease.
Glucagon: A 29-amino-acid pancreatic hormone that raises blood glucose; used as a rescue medicine for severe low blood sugar and as a diagnostic aid.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.